Swine Vaccine Brazilian Marketing Authorisation

7 January 2021

ECO Animal Health Group plc

("ECO", "the Company" or the "Group")

(AIM: EAH)

BRAZILIAN MARKETING AUTHORISATION FOR SWINE VACCINE

ECO Animal Health Group plc is pleased to announce that it has received a marketing authorisation from Brazil's Ministry of Agriculture, Livestock and Food Supply for Circo/MycoGard®, a vaccine for swine.

Circo/MycoGard® is used for the vaccination of healthy piglets against Porcine Circovirus type 2 ("PCV2") and Mycoplasma hyopneumoniae, two of the most common primary pig respiratory disease pathogens affecting the health and productivity of swine globally.

This marketing authorisation is the first licence obtained by ECO-Pharm Limited, a joint venture established in the Republic of Ireland in 2018 between ECO Animal Health Ltd, a wholly owned subsidiary of the Group, and Pharmgate Corp ("Pharmgate") of Wilmington, North Carolina, USA responsible for the registration, marketing, sale and distribution of a number of Pharmgate LLC swine vaccine products.

Marc Loomes, CEO said: "Brazil is a globally important swine market which is reaching record pork export levels. This first vaccine marketing authorisation in Brazil marks a significant milestone as we build our capability with vaccines and broaden our product portfolio. The speed with which Circo/MycoGard® was approved in Brazil under difficult circumstances is most gratifying and a credit to the team."

Colin Gray, President and CEO of Pharmgate commented: "Our joint international efforts are vitally important to the long term growth of our companies. I am very pleased with our teams and the work they have accomplished in getting our first vaccine into this highly important market. I look forward to similar success over the coming months and years."

Contacts: 

 Notes:

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

Pharmgate Corp is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline and other fermentation compounds, and more recently, the majority owner of Hangzhou UBEN Animal Vaccine Co., Ltd., a company manufacturing and supplying vaccines to the domestic market in China.

ECO and Pharmgate have jointly established Pharmgate Animal Health in the United States of America (2010) and Canada (2011) where these successful operations market their owners' product portfolios for livestock.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.